LITTLE KNOWN FACTS ABOUT WHAT ARE THE BEST NEUROPROTECTIVE DRUGS?.

Determined by the subgroup analysis, we observed that there was substantial heterogeneity in terms of mortality, favorable outcomes, and the overall therapy productive price. Pertaining to mortality, the reason for heterogeneity about the subgroup of edaravone dexborneol and EDV was predominantly attributed to variations in drug dosage. With regard